Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 12/20 | 0.39 |
| ▸ | ERBB2 | P04626 | 8/20 | 0.38 |
| ▸ | NQO2 | P16083 | 1/20 | 0.38 |
| ▸ | FECH | P22830 | 1/20 | 0.38 |
| ▸ | MYH14 | Q7Z406 | 1/20 | 0.38 |
| ▸ | RIPK3 | Q9Y572 | 1/20 | 0.38 |
| ▸ | BRAF | P15056 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25430846 | 0.87 | EGFR (0.50) | EGFRERBB2NQO2FECHMYH14 | |
| SCHEMBL30575829 | 0.87 | EGFR (0.50) | EGFRERBB2NQO2FECHMYH14 | |
| SCHEMBL25429223 | 0.86 | EGFR (0.38) | EGFRERBB2NQO2FECHMYH14 | |
| SCHEMBL25430634 | 0.83 | EGFR (0.45) | EGFRERBB2NQO2FECHMYH14 | |
| SCHEMBL30575827 | 0.83 | EGFR (0.45) | EGFRERBB2NQO2FECHMYH14 | |
| SCHEMBL30575855 | 0.82 | ERBB2 (0.56) | EGFRERBB2NQO2FECHMYH14 | |
| SCHEMBL25431043 | 0.82 | ERBB2 (0.56) | EGFRERBB2NQO2FECHMYH14 | |
| SCHEMBL26008934 | 0.82 | BRAF (0.43) | EGFRERBB2BRAF | |
| Hydrochloric Acid SCHEMBL25353465 | 0.81 | BRAF (0.43) | EGFRERBB2BRAF | |
| SCHEMBL25431888 | 0.81 | BRAF (0.43) | BRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250136595-A1 | ACYLATED HETEROCYCLIC QUINAZOLINE DERIVATIVES AS INHIBITORS OF ERBB2 | ENLIVEN INC. | 2025-05-01 | — | — | US | disclosed |
| EP-4476211-A1 | ACYLATED HETEROCYCLIC QUINAZOLINE DERIVATIVES AS INHIBITORS OF ERBB2 | Enliven Inc. (US) | 2024-12-18 | — | — | EP | disclosed |
| WO-2023154124-A1 | ACYLATED HETEROCYCLIC QUINAZOLINE DERIVATIVES AS INHIBITORS OF ERBB2 | ENLIVEN THERAPEUTICS, INC. (US) | 2023-08-17 | — | — | WO | disclosed |
| WO-2023154124-A1 | ACYLATED HETEROCYCLIC QUINAZOLINE DERIVATIVES AS INHIBITORS OF ERBB2 | ENLIVEN THERAPEUTICS, INC. (US) | 2023-08-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250136595-A1 | ACYLATED HETEROCYCLIC QUINAZOLINE DERIVATIVES AS INHIBITORS OF ERBB2 | ERBB2, ERBB3, ERBB4 | EGFR 5/4885ERBB2 1/4885NQO2 740/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.